

Hrk BH3 Domain Antibody Blocking Peptide

Synthetic peptide Catalog # BP1311a

Specification

Hrk BH3 Domain Antibody Blocking Peptide - Product Information

Primary Accession O00198
Other Accession NP 003797

Hrk BH3 Domain Antibody Blocking Peptide - Additional Information

Gene ID 8739

Other Names

Activator of apoptosis harakiri, BH3-interacting domain-containing protein 3, Neuronal death protein DP5, HRK, BID3

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP1311a was selected from the region of human Hrk BH3 Domain. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

Hrk BH3 Domain Antibody Blocking Peptide - Protein Information

Name HRK

Synonyms BID3

Function

Promotes apoptosis.

Cellular Location

Membrane; Single-pass membrane protein. Mitochondrion

Hrk BH3 Domain Antibody Blocking Peptide - Protocols



Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

Hrk BH3 Domain Antibody Blocking Peptide - Images

Hrk BH3 Domain Antibody Blocking Peptide - Background

Activator of apoptosis Hrk regulates apoptosis through interaction with death-repressor proteins Bcl-2 and Bcl-X(L). The HRK protein lacks significant homology to other BCL2 family members except for an 8-amino acid region that was similar to the BCL2 homology domain-3 (BH3) motif of BIK. HRK interacts with BCL2 and BCLXL via the BH3 domain, but not with the death-promoting BCL2-related proteins BAX, BAK, or BCLXS. HRK localizes to membranes of intracellular organelles in a pattern similar to that previously reported for BCL2 and BCLXL.

Hrk BH3 Domain Antibody Blocking Peptide - References

Wakabayashi, T., et al., Neurosci. Lett. 318(2):77-80 (2002).Inohara, N., et al., EMBO J. 16(7):1686-1694 (1997).